Phase 3
N=623
Trichomonas Vaginalis Repeat Infections Among HIV Negative Women
Vaginitis Trichomonal or Due to Trichomonas
Bottom Line
View on ClinicalTrials.gov: NCT01832480 ↗Enrolled (actual)
623
Serious AEs
0.3%
Results posted
Feb 2019
Primary outcome: Primary: Number of Subjects That Were Trichomonas Vaginalis (TV) Positive After Treatment With Metronidazole (MTZ) — 58; 34 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- MTZ 500 mg twice daily x 7 days (Drug); MTZ 2 g (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Tulane University Health Sciences Center
- Primary completion
- Jun 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Subjects That Were Trichomonas Vaginalis (TV) Positive After Treatment With Metronidazole (MTZ) |
58; 34 | — |
Summary
The overall goal of this project is to determine the influence of patient treatment and host factors on repeat Trichomonas vaginalis (TV) infections among HIV-negative women
Eligibility Criteria
Inclusion Criteria
- female
- English speaking
- >= 18 years old
Exclusion Criteria
- HIV-infected
- unable to provide informed consent
- pregnant
- breast feeding
- treated by their provider for Bacterial vaginosis (BV) at visit
Data sourced from ClinicalTrials.gov (NCT01832480). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.